A new obesity treatment targeting the melanocortin system has emerged. Kalohexis, a clinical-stage biotech company spun out from Endevica Bio in March 2026, has filed a confidential registration statement with the U.S. Securities and Exchange Commission (SEC) to raise capital. The primary goal of this IPO is to accelerate the development of its pipeline of melanocortin-3/4 receptor (MC3R/MC4R) dual agonists, which aim to compete with existing market leaders such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, both GLP-1-based drugs. Kalohexis' lead pipeline candidate, 710GO, has a unique mechanism of action that directly alters the body's metabolic set-point by regulating the melanocortin system located in the hypothalamus. This approach is intended to overcome the limitations of existing GLP-1 treatments, which rely on simple appetite suppression and often lead to rapid weight regain upon discontinuation, as well as associated side effects.

The next-generation drug candidate aims to overcome muscle loss and gastrointestinal side effects. 710GO, which is being developed as an oral formulation for convenient administration, initiated its first-in-human Phase 1 trial in Australia in May 2026, and is diligently evaluating its safety and tolerability in overweight and obese adults. According to preclinical data provided by the company, 710GO did not show any significant reduction in lean body mass or gastrointestinal distress, such as vomiting and diarrhea, which are commonly observed with GLP-1 receptor agonists. This could be a significant competitive advantage as preserving muscle mass becomes a standard in new obesity treatments, and it could dramatically improve compliance among chronic patients. If the Phase 1 results confirm the preclinical safety and muscle-preserving efficacy, it could be a game-changer in addressing the unmet needs in the global obesity treatment market.

The company is also accelerating the development of a first-in-class drug for cancer cachexia. Kalohexis is also focusing on developing a treatment for cancer cachexia, a debilitating condition that affects patients with advanced cancer. Its other key asset, Mifomelatide (formerly TCMCB07), is a dual MC3R/MC4R antagonist in a Phase 2 study. Cancer cachexia causes rapid weight loss and muscle wasting, which can impair cancer patients' ability to tolerate chemotherapy and reduce their survival rates. However, there are currently no standard treatments available. Mifomelatide's unique approach of blocking abnormal catabolic signals in the brain through melanocortin receptor antagonism and directly preventing muscle wasting is expected to create a unique opportunity in the cancer supportive care market.

The recent IPO filing reflects the positive sentiment in the biotech IPO market and the strategic importance of raising capital. This confidential IPO filing comes after Kailera Therapeutics successfully completed a large IPO of $625 million, reflecting the strong investor interest in the U.S. obesity treatment market. While the specific number of shares and price range for the IPO have not yet been determined, the capital raised will be used to fund the global Phase 2 trial of 710GO and the late-stage clinical trials of Mifomelatide. The company's spin-out structure from Endevica Bio allows for rapid decision-making, which can accelerate the development of metabolic disease treatments. This is also expected to give the company a significant advantage in negotiating licensing deals with large global pharmaceutical companies in the future.